Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock‐Ah Im(Seoul National University), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Nadia Harbeck(Breast Center), Ioannis Gounaris(Novartis (Switzerland)), Joohyuk Sohn(Yonsei University), Aditya Bardia(UCLA Health), Saúl Campos-Gómez(National Cancer Center), Marco Colleoni(European Institute of Oncology), Keun-Seok Lee(National Cancer Center), Gareth Hughes(University of Greater Manchester), Sara A. Hurvitz(University of Washington), Fábio Franke(National Cancer Center), Rafael Villanueva-Vázquez(National Cancer Center), Louis W.C. Chow(National Cancer Center), Arunava Chakravartty(National Cancer Center), Kyung-Hae Jung(Ulsan College), Karen Rodriguez-Lorenc(National Cancer Center), Tetiana Taran(National Cancer Center), Yen‐Shen Lu(National Taiwan University Hospital)
Cited by 1,017
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k